Having trouble reading this email? View it on your browser.

Catalyst Corner is pleased to announce a new Featured Company: Soligenix, Inc.  

Soligenix, Inc. (OTCQB: SNGX) is a clinical stage biopharmaceutical company developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. 

 

The Soligenix management team is led by Christopher J. Schaber, PhD. Dr. Schaber has served in this role since 2006. Prior to joining Soligenix Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc.

 

The Soligenix board includes Dr. Jerome Zeldis MD, PhD, who has been a director since June 22, 2011. Dr. Zeldis is currently Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation.

 

Soligenix operates in two divisions: 

  1. BioTherapeutics – focusing on orphan diseases and areas of unmet medical need
  2. BioDefense – focusing on developing countermeasures for inclusion in the US Government’s Strategic National Stockpile

BioTherapeutics Division

Soligenix is developing proprietary formulations of oral BDP for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including: 

  • Pediatric Crohn's disease (SGX203) 
  • Acute radiation enteritis (SGX201)
  • Chronic Graft-versus-Host disease (orBec®)

BioDefense Division

Soligenix BioDefense Division is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. 

 

Soligenix's lead biodefense products in development are:

  • RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin 
  • VeloThrax™, a vaccine against anthrax exposure

Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant.  To date, development of OrbeShield™ has been largely supported by a $1 million NIH grant to Soligenix's academic partner, the Fred Hutchinson Cancer Research Center. 

 

Soligenix announced a worldwide exclusive collaboration with Intrexon Corporation that will focus on the joint development of a treatment for Melioidosis. Inxtrexon is run by billionaire R.J. Kirk, considered to be one of the most successful biotech company developers in the United States. 

 

Soligenix goal is to develop a therapy that will treat both a deadly disease currently affecting millions of people as well as fight a potential biological weapon.

 

A video featuring Soligenix can be found at: www.catalystcorner.com 

 

Further information can be found in the SNGX fact sheet in or on the Soligenix website: http://www.soligenix.com/

*The Catalyst Corner Pair Tool is for informational and educational purposes only and should not be considered as a recommendation to buy or sell securities of any kind. Historical individual security and pair performance is no guarantee of future performance.







This email communication is privileged, confidential or otherwise protected by disclosure and is intended only for the individuals or entities named above. Any unauthorized distribution, dissemination, copying or use of the contents of this email is strictly prohibited and may be in violation of law. If you are not the intended recipient, please do not review, copy, use or disclose the contents of this email. If you have received this email in error, please delete it from your computer and notify the sender by reply e-mail. Catalyst Corner LLC does not accept liability for any content contained in this email, or any errors, omissions, delays of receipt or viruses arising as a result of email transmission. The information contained in this email should not be considered as an offer or a solicitation of an offer to buy or sell securities. A fee has been paid to Catalyst Corner LLC in the amount of $1,000 on behalf of Soligenix, lnc. (SNGX) for promotional services including email distribution by Catalyst Corner LLC. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of Catalyst Corner LLC or its affiliates. In compliance with applicable rules and regulations, Catalyst Corner LLC reserves the right to review and archive all incoming and outgoing email communications.


© 2017 Catalyst Corner™, 450 Seventh Avenue New York, NY 10123